Cardiol Therapeutics (CRDL) Competitors $1.27 -0.02 (-1.16%) As of 12:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDL vs. KURA, SEPN, ABVX, MAZE, PRME, VALN, BCAX, PGEN, SIGA, and ATYRShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Kura Oncology (KURA), Septerna (SEPN), Abivax (ABVX), Maze Therapeutics (MAZE), Prime Medicine (PRME), Valneva (VALN), Bicara Therapeutics (BCAX), Precigen (PGEN), Siga Technologies (SIGA), and aTyr Pharma (ATYR). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Its Competitors Kura Oncology Septerna Abivax Maze Therapeutics Prime Medicine Valneva Bicara Therapeutics Precigen Siga Technologies aTyr Pharma Cardiol Therapeutics (NASDAQ:CRDL) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership. Do insiders & institutionals hold more shares of CRDL or KURA? 12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 6.4% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate CRDL or KURA? Cardiol Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 527.45%. Kura Oncology has a consensus target price of $24.50, suggesting a potential upside of 278.96%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cardiol Therapeutics is more favorable than Kura Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more risk & volatility, CRDL or KURA? Cardiol Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Does the media refer more to CRDL or KURA? In the previous week, Kura Oncology had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Kura Oncology and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.89 beat Kura Oncology's score of 1.31 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cardiol Therapeutics Very Positive Kura Oncology Positive Which has preferable valuation and earnings, CRDL or KURA? Cardiol Therapeutics has higher earnings, but lower revenue than Kura Oncology. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiol TherapeuticsN/AN/A-$26.77M-$0.34-3.75Kura Oncology$67.99M8.23-$173.98M-$2.10-3.08 Is CRDL or KURA more profitable? Kura Oncology's return on equity of -43.62% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cardiol TherapeuticsN/A -209.63% -141.09% Kura Oncology N/A -43.62%-29.13% SummaryCardiol Therapeutics and Kura Oncology tied by winning 7 of the 14 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.30M$2.43B$5.56B$9.26BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-3.759.1428.5819.56Price / SalesN/A711.83434.47183.65Price / CashN/A164.3436.0257.93Price / Book5.804.658.165.58Net Income-$26.77M$30.99M$3.24B$257.82M7 Day Performance-8.27%-0.08%-0.64%-0.39%1 Month Performance-10.84%7.08%4.93%7.80%1 Year Performance-42.05%-6.56%26.04%12.95% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics2.4309 of 5 stars$1.28-1.2%$8.00+527.5%-39.4%$105.30MN/A-3.7520Positive NewsKURAKura Oncology4.5577 of 5 stars$5.68-3.1%$24.50+331.3%-73.1%$507.33M$53.88M0.00130SEPNSepterna1.5264 of 5 stars$10.85-4.6%$26.75+146.5%N/A$506.63M$1.08M0.00N/AABVXAbivax2.2424 of 5 stars$7.95-0.1%$31.00+289.9%-35.6%$505.10MN/A0.0061News CoveragePositive NewsGap UpHigh Trading VolumeMAZEMaze TherapeuticsN/A$12.12+5.4%$25.67+111.8%N/A$503.67M$167.50M0.00121PRMEPrime Medicine3.8533 of 5 stars$3.80+22.2%$10.08+165.4%-25.8%$498.92M$3.85M-1.85234High Trading VolumeVALNValneva1.7985 of 5 stars$5.75-1.0%$15.50+169.6%-12.8%$494.40M$183.52M0.00700Gap DownBCAXBicara TherapeuticsN/A$9.01-0.2%$31.86+253.6%N/A$492.46MN/A0.0032PGENPrecigen4.037 of 5 stars$1.59-1.9%$6.00+277.4%+12.5%$478.19M$3.92M0.00190News CoverageAnalyst RevisionSIGASiga Technologies2.2206 of 5 stars$6.73+0.6%N/A-26.6%$477.94M$138.72M9.9940News CoverageATYRaTyr Pharma2.0536 of 5 stars$5.30-0.2%$20.20+281.1%+219.0%$472.61M$230K0.0053High Trading Volume Related Companies and Tools Related Companies KURA Alternatives SEPN Alternatives ABVX Alternatives MAZE Alternatives PRME Alternatives VALN Alternatives BCAX Alternatives PGEN Alternatives SIGA Alternatives ATYR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDL) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
